Archives

Shahin Gharakhanian MD Consulting LLC ANNUAL 2023 REPORT

Selected 2023 projects and workflows (alphabetically ordered): BIOPHTA (Paris, France). US Executive Advisor. BIOPHTA aims to radically change eye treatments for various ophtalmological diseases that require daily eye drops or repeated intraocular injections. BIOPHTA technology of drug delivery improve treatment efficacy by leveraging a micro...

Continue reading »

Shahin Gharakhanian, co-founder and Program Chair of the 7th Boston Paris Biotechnology Summit held 4 June 2023, International BIO Convention week Boston MA.

Summit Mission An exclusive, Trans-Atlantic bridge designed to foster innovative synergies between biotech and pharma companies, healthcare-focused cities, and regional clusters, institutional, philanthropic and strategic investors. The Summit’s intent is to spark projects, their financings and strategic deals to solve unmet medical needs...

Continue reading »

Shahin Gharakhanian MD Consulting LLC 2022 ANNUAL PROJECTS REPORT

[ACTICOR-BIOTECH, Paris, France] US Medical Executive @ Acticor-Biotech ACTISAVE Study – ClinicalTrials.gov Identifier: NCT05070260. Adaptive Efficacy and Safety Study of Glenzocimab Used as an add-on Therapy on Top of Standard of Care un the 4.5 Hours Following an Acute Ischemic Stroke (ACTISAVE) DECOY Therapeutics, Cambridge, MA,...

Continue reading »

Shahin Gharakhanian MD Consulting LLC, 2022 Mid-Year Report:

Selected Projects listed in alphabetical order: [ACTICOR-BIOTECH, Paris, France] US Medical Executive for Acticor BiotechDeveloping Glenzocimab, a humanized monoclonal antibody fragment directed against platelets glycoprotein VI (GPVI). Primary Indication = Stroke.ACTISAVE phase II/III Study [(NCT05070260] ongoing.Please refer to : www.acticor-biotech.com [DECOY...

Continue reading »

[Sept 2021] Presentation @ Vaccine (Virtual) Summit 2021

Prevention of Covid-19 Transmission Beyond the Needle: DCOY101, a novel antiviral fusion peptide-based prophylactic nasal spray. Barbara Hibner*, Peter Marschel*, Frederick E. Pierce II*, Shahin Gharakhanian** *Research & Development Program Team, **Scientific Advisory Board, DECOY Therapeutics, CAMBRIDGE MA, USA. [Contact:...

Continue reading »

Shahin Gharakhanian MD 1H2021 COVID-19 Activities’ PROGRESS REPORT

* Utay, N. S., Asmuth, D. M, Gharakhanian, S., Contreras, M., Warner, C. D., & Detzel, C. J. (2021). Potential use of serum-derived bovine immunoglobulin/protein isolate for the management ofCOVID-19. Drug Development Research, 1–7. https://doi.org/10.1002/ddr.21841 * GARDEN (NCT04659109) is a multinational, multicenter, randomized, double-blind,...

Continue reading »

Shahin Gharakhanian MD 2020 COVID-19 Activities’ REPORT

On 30 December 2019 a ProMed email from the International Society of Infectious Diseases (IDSA) contained information on <Undiagnosed pneumonia in China>, thus alerting the world to what was to become the worst health crisis in 100 years. On 24 January 2020, the New England Journal of Medicine (2020, 382: 727-733) published a brief report from...

Continue reading »